Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Genedrive ( (GB:GDR) ) just unveiled an update.
Genedrive plc announced that its Genedrive® CYP2C19-ID Kit will be used in a trial led by Manchester University Foundation Trust to support the expansion of its use to include Acute Coronary Syndrome (ACS). The trial, in collaboration with the GUIDE PCI programme and the British Heart Foundation, aims to assess the value and feasibility of rapid point-of-care CYP2C19 testing in cardiovascular disease to improve patient outcomes. This initiative aligns with recommendations from the American Heart Association for rapid genetic testing in cardiovascular indications and aims to integrate the Genedrive® CYP2C19-ID Kit into routine clinical practice. The trial will help establish the feasibility and value of this intervention, potentially leading to wider adoption across other centers, thus improving patient outcomes and optimizing healthcare resources.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive’s overall score reflects strong revenue growth and a healthy balance sheet, offset by ongoing profitability challenges and negative cash flows. Technical indicators suggest bearish momentum, while positive corporate events, including new funding and strategic partnerships, provide a potential upside.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes rapid, cost-effective, and easy-to-use point-of-care testing platforms. These platforms are designed to provide clinicians with crucial genetic information to make informed decisions on medication and dosages, particularly in emergency healthcare settings. The company has launched two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both of which are recommended for use by the UK NHS and have been developed in collaboration with NHS partners.
Average Trading Volume: 4,580,297
Technical Sentiment Signal: Strong Sell
Current Market Cap: £9.28M
For detailed information about GDR stock, go to TipRanks’ Stock Analysis page.